Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AIM ImmunoTech Inc. Common Stock (NY:AIM)

0.0949 -0.0228 (-19.37%)
Streaming Delayed Price Updated: 10:10 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AIM ImmunoTech Inc. Common Stock

< Previous 1 2 3 4 Next >
Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For March 28, 2025
Via Benzinga
Earnings Preview For AIM ImmunoTech
Via Benzinga
Insights into AIM ImmunoTech's Upcoming Earnings
Via Benzinga
Exploring AIM ImmunoTech's Earnings Expectations
Via Benzinga
AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024
AIM stock results show that AIM ImmunoTech missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Preview: AIM ImmunoTech's Earnings
Via Benzinga
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025. 
Via Stocktwits
Earnings Scheduled For November 15, 2024
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AIM Stock Earnings: AIM ImmunoTech Beats EPS, Beats Revenue for Q2 2024
AIM stock results show that AIM ImmunoTech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
AIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023
AIM stock results show that AIM ImmunoTech missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Preview: AIM ImmunoTech's Earnings
Via Benzinga
Earnings Outlook For AIM ImmunoTech
Via Benzinga
Earnings Scheduled For April 2, 2024
Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. 
Via Benzinga
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning! 
Via InvestorPlace
AIM ImmunoTech And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested... 
Via Benzinga
Topics Stocks
Exposures US Equities
NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed lower by more than 150 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Cancer Focused Microcap Stock AIM ImmunoTech Trading Higher Today?
AIM ImmunoTech Inc (NYSE: AIM) announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen (rintatolimod) as a component of... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By 21%; Here Are 20 Stocks Moving Premarket
Gainers BioNexus Gene Lab Corp. (NASDAQ: BGLC) shares gained 48.5% to $2.05 in pre-market trading after jumping 30% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.